Guideline on clinical investigation of medicinal products for the treatment of venous thromboembolic
Venous thromboembolism (VTE) is the third leading cause of death due to circulatory diseases, only behind of myocardial infarction and stroke. Since the publication of the CPMP guidance on clinical investigation of medicinal products for the treatment of venous thromboembolic disease [CPMP/EWP/563/98] in 2000 [2], there has been intense research in this field. An update of the mentioned guideline is considered necessary to adapt its content to current scientific knowledge and to harmonise it with the content of new or revised EMA guidelines related to clinical investigation with antithrombotics.
Click on this link for more information.
